Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 15/20 | 0.44 |
| ▸ | CDK9 | P50750 | 15/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | QDPR | P09417 | 1/20 | 0.39 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5397403 | 0.88 | ADORA1 (0.46) | ADORA1CCNT1CDK9 | |
| SCHEMBL5396722 | 0.87 | ADORA1 (0.50) | ADORA1ADORA2A | |
| SCHEMBL5392823 | 0.85 | MAPK1 (0.46) | ADORA1ADORA2A | |
| SCHEMBL5405421 | 0.83 | ADORA1 (0.53) | ADORA1CCKARADORA2A | |
| SCHEMBL5405504 | 0.82 | PRKCZ (0.55) | ADORA1CCKARADORA2A | |
| SCHEMBL5404432 | 0.82 | ADORA1 (0.52) | ADORA1CCKARADORA2A | |
| SCHEMBL5404667 | 0.82 | ADORA1 (0.52) | ADORA1ABCB1ADORA2A | |
| SCHEMBL5400730 | 0.80 | ADORA1 (0.49) | ADORA1CCKARADORA2A | |
| SCHEMBL5405217 | 0.80 | ADORA1 (0.50) | ADORA1CCKARADORA2A | |
| SCHEMBL27582134 | 0.79 | ADORA1 (0.48) | ADORA1CCKARADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | claimed |
| US-6743791-B2 | ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-01 | — | — | US | claimed |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAPKAPK2 | ADORA1 4421/4885CCNT1 623/4885CDK9 1155/4885 |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | ADORA1 4106/4885CCNT1 205/4885CDK9 500/4885 |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | ADORA1 4106/4885CCNT1 205/4885CDK9 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.